Showing 1 - 1 results of 1 for search 'Kyle Current', query time: 0.02s Refine Results
  1. 1
    717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

    717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand t... by Caius Radu, Mark Salvati, Julie Bailis, Katharina Lueckerath, Kyle Current, Johannes Czernin

    Published 2020-11-01
    Article

Search Tools: